Basit öğe kaydını göster

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

dc.contributor.authorKarakiewicz, Pierre I.
dc.contributor.authorBodrogi, Istvan
dc.contributor.authorMiller, Kurt
dc.contributor.authorBavbek, Sevil E.
dc.contributor.authorGruenwald, Viktor
dc.contributor.authorPirotta, Nicoletta
dc.contributor.authorBooth, Jocelyn
dc.contributor.authorRosamilia, Marianne
dc.contributor.authorAnak, Oezlem
dc.contributor.authorHawkins, Robert
dc.contributor.authorKnox, Jennifer J.
dc.contributor.authorBlank, Christian U.
dc.contributor.authorCastellano, Daniel
dc.contributor.authorRha, Sun Young
dc.contributor.authorBono, Petri
dc.contributor.authorLarkin, James
dc.contributor.authorLee, Se-Hoon
dc.contributor.authorMachiels, Jean-Pascal
dc.date.accessioned2021-03-05T19:38:52Z
dc.date.available2021-03-05T19:38:52Z
dc.date.issued2012
dc.identifier.citationGruenwald V., Karakiewicz P. I. , Bavbek S. E. , Miller K., Machiels J., Lee S., Larkin J., Bono P., Rha S. Y. , Castellano D., et al., "An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy", EUROPEAN JOURNAL OF CANCER, cilt.48, ss.324-332, 2012
dc.identifier.issn0959-8049
dc.identifier.othervv_1032021
dc.identifier.otherav_d0347c4b-4377-40d0-b169-b98e33420c9a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/137654
dc.identifier.urihttps://doi.org/10.1016/j.ejca.2011.06.054
dc.description.abstractBackground and objectives: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC.
dc.language.isoeng
dc.subjectTıp
dc.subjectONKOLOJİ
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectOnkoloji
dc.titleAn international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF CANCER
dc.contributor.departmentHannover Medical School , ,
dc.identifier.volume48
dc.identifier.issue3
dc.identifier.startpage324
dc.identifier.endpage332
dc.contributor.firstauthorID203540


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster